share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer KASINGER JAMES R.

SEC announcement ·  Feb 22 06:52
Summary by Futu AI
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, completed a sale of 1,913 common shares on February 20, 2024. The transaction was executed at a price of $79.67 per share, resulting in a total market value of $152,408.71. Prior to this sale, Kasinger acquired 3,825 shares through the exercise of derivative securities on February 18, 2024. Following these transactions, Kasinger's direct holdings in CRISPR Therapeutics amount to 57,371 common shares. The sale represents an open market transaction, and the acquisition was a result of exercising options available to Kasinger.
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, completed a sale of 1,913 common shares on February 20, 2024. The transaction was executed at a price of $79.67 per share, resulting in a total market value of $152,408.71. Prior to this sale, Kasinger acquired 3,825 shares through the exercise of derivative securities on February 18, 2024. Following these transactions, Kasinger's direct holdings in CRISPR Therapeutics amount to 57,371 common shares. The sale represents an open market transaction, and the acquisition was a result of exercising options available to Kasinger.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.